Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 10433947)

1.
4.

Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.

Fang D, Hallman J, Sangha N, Kute TE, Hammarback JA, White WL, Setaluri V.

Am J Pathol. 2001 Jun;158(6):2107-15.

6.

Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.

Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M.

Cancer Res. 1989 Sep 15;49(18):5091-6.

7.

Increased expression of stem cell markers in malignant melanoma.

Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR.

Mod Pathol. 2007 Jan;20(1):102-7. Epub 2006 Nov 24.

8.

Melanoma-associated expression of transforming growth factor-beta isoforms.

Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE.

Am J Pathol. 1996 Jun;148(6):1887-94.

9.

p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.

Sparrow LE, Eldon MJ, English DR, Heenan PJ.

Am J Dermatopathol. 1998 Jun;20(3):255-61.

PMID:
9650698
10.

Expression of nerve growth factor and epidermal growth factor receptors in neural nevi with nevic corpuscles.

Argenyi ZB, Rodgers J, Wick M.

Am J Dermatopathol. 1996 Oct;18(5):460-4.

PMID:
8902091
11.

A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.

Clark WH Jr, Elder DE, Guerry D 4th, Epstein MN, Greene MH, Van Horn M.

Hum Pathol. 1984 Dec;15(12):1147-65.

PMID:
6500548
12.

The p75 neurotrophin receptor, relative to other Schwann cell and melanoma markers, is abundantly Expressed in spindled melanomas.

Iwamoto S, Burrows RC, Agoff SN, Piepkorn M, Bothwell M, Schmidt R.

Am J Dermatopathol. 2001 Aug;23(4):288-94.

PMID:
11481518
13.

Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin.

Bröcker EB, Magiera H, Herlyn M.

J Invest Dermatol. 1991 May;96(5):662-5.

PMID:
1850772
14.

Proliferative activity of primary cutaneous melanocytic tumours.

Kuwata T, Kitagawa M, Kasuga T.

Virchows Arch A Pathol Anat Histopathol. 1993;423(5):359-64.

PMID:
7906909
15.

IMP-3 is a novel progression marker in malignant melanoma.

Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H.

Mod Pathol. 2008 Apr;21(4):431-7. doi: 10.1038/modpathol.3801016. Epub 2008 Jan 18.

16.

Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.

Yu L, Harms PW, Pouryazdanparast P, Kim DS, Ma L, Fullen DR.

Mod Pathol. 2010 Sep;23(9):1209-14. doi: 10.1038/modpathol.2010.101. Epub 2010 May 21.

18.
19.

Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.

Simonetti O, Lucarini G, Brancorsini D, Nita P, Bernardini ML, Biagini G, Offidani A.

Cancer. 2002 Nov 1;95(9):1963-70.

20.

Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.

Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M.

J Pathol. 2001 Jun;194(2):194-200.

PMID:
11400148
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk